- U.S. launch of therascreen ® KRAS RGQ PCR Kit offers enhanced approach to guide treatments for approximately 110 ,000 patients annually in U.S. with colorectal cancer
- First FDA approval of a QIAGEN companion diagnostic marks a milestone in its global expansion of rapidly growing Personalized Healthcare business
- Important cancer assay adds valuable content for an expanding QIAGEN automation platform
QIAGEN Achieves Personalized Healthcare Milestone With U.S. Approval Of Companion Diagnostic For Colorectal Cancer
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts
More than 30 investing pros with skin in the game give you actionable insight and investment ideas.